Robert Naclerio to Nasal Polyps
This is a "connection" page, showing publications Robert Naclerio has written about Nasal Polyps.
Connection Strength
7.536
-
Unblocking the Treatment Stalemate in Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP). J Allergy Clin Immunol Pract. 2024 Apr; 12(4):1062-1064.
Score: 0.920
-
A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012-2022. J Allergy Clin Immunol Pract. 2023 01; 11(1):43-50.
Score: 0.844
-
The Treatment Paradigm of Chronic Rhinosinusitis with Nasal Polyps in the COVD-19 Era. J Allergy Clin Immunol Pract. 2020 09; 8(8):2492-2494.
Score: 0.708
-
Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. J Allergy Clin Immunol Pract. 2020 05; 8(5):1532-1549.e1.
Score: 0.693
-
Persistence of Sinonasal Disease Despite Mepolizumab. J Allergy Clin Immunol Pract. 2020 05; 8(5):1550-1555.
Score: 0.690
-
Uncharted Waters: Challenges in the Era of Biologic Therapies for Nasal Polyposis. J Allergy Clin Immunol Pract. 2019 01; 7(1):68-70.
Score: 0.626
-
Nasal Polyps and Biomarkers. J Allergy Clin Immunol Pract. 2017 Nov - Dec; 5(6):1589-1590.
Score: 0.590
-
Diagnostic algorithm for unilateral sinus disease: a 15-year retrospective review. Int Forum Allergy Rhinol. 2015 Jul; 5(7):590-6.
Score: 0.494
-
Evidence-based approach to medical and surgical treatment of nasal polyposis. J Allergy Clin Immunol. 2013 Dec; 132(6):1461-1462.e3.
Score: 0.449
-
Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol. 2013 Jul; 132(1):247.
Score: 0.433
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy. 2021 08; 76(8):2337-2353.
Score: 0.187
-
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology. 2020 Feb 01; 58(1):10-17.
Score: 0.172
-
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy. 2020 01; 75(1):148-157.
Score: 0.169
-
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. J Allergy Clin Immunol Pract. 2019 Sep - Oct; 7(7):2447-2449.e2.
Score: 0.162
-
Monoclonal Antibodies for the Treatment of Nasal Polyps. Immunol Allergy Clin North Am. 2017 05; 37(2):357-367.
Score: 0.141
-
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016 Feb; 6 Suppl 1:S22-209.
Score: 0.131
-
Decreased neuropeptide release may play a role in the pathogenesis of nasal polyps. Otolaryngol Head Neck Surg. 1999 Nov; 121(5):585-90.
Score: 0.042
-
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA. 2016 Feb 02; 315(5):469-79.
Score: 0.033
-
Rhinosinusitis: Developing guidance for clinical trials. Otolaryngol Head Neck Surg. 2006 Nov; 135(5 Suppl):S31-80.
Score: 0.017
-
Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol. 2006 Nov; 118(5 Suppl):S17-61.
Score: 0.017
-
Sinusitis: bench to bedside. Current findings, future directions. J Allergy Clin Immunol. 1997 Jun; 99(6 Pt 3):S829-48.
Score: 0.009
-
Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol Head Neck Surg. 1997 Jun; 116(6 Pt 2):S1-20.
Score: 0.009